Jason Bradt

Astellas Pharma (United States)

Papers

1

Total Citations

33

H-Index

1

About

Jason Bradt is a leading urologic researcher whose work centers on improving postoperative outcomes for prostate cancer patients, with a particular focus on urinary continence recovery after robotic-assisted radical prostatectomy. His most cited study, a landmark Phase 4 multicenter trial published in 2014, rigorously evaluated the efficacy of solifenacin succinate versus placebo in accelerating return to continence for patients still experiencing leakage 7 to 21 days after catheter removal. This double-blind, randomized investigation provided critical evidence on pharmacological management of post-prostatectomy bladder dysfunction, directly addressing a major quality-of-life concern for thousands of men. With 33 citations, the study has shaped clinical protocols and sparked further research into targeted therapies for postoperative incontinence. Bradt’s work exemplifies the translation of rigorous clinical trial design into practical, patient-centered care, offering hope and tangible solutions for recovery. His contributions continue to influence urologic oncology and rehabilitation, making him a respected voice in the field.

Research Focus

Key Achievements

1
H-Index
1
Papers
33
Total Citations
33
Avg Citations/Paper
🏆 Most Cited Paper
A Randomized, Double-Blind, Solifenacin Succinate versus Placebo Control, Phase 4, Multicenter Study Evaluating Urinary Continence after Robotic Assisted Radical Prostatectomy
33 citations · 2014
📈 Most Prolific Year: 2014 (1 Papers)
🤝 Key Collaborators: 8
🏛 Institutions: Astellas Pharma (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago